An initial safety trial of a potential coronavirus vaccine produced antibodies to the deadly disease in everyone who was tested, according to a report.
The neutralizing antibodies produced by Moderna Inc.’s vaccine were equivalent to the upper half of what’s seen in patients who get infected and recover, Bloomberg News said.
Meanwhile, the side effects of the vaccine weren’t bad enough to halt the testing process, Bloomberg said, citing results reported by government researchers in the New England Journal of Medicine.
Stimulating the production of antibodies is considered a key milestone in early testing, but doesn’t prove a vaccine will be effective, Bloomberg said. The test results were based on data involving the first 45 people enrolled in the study, all of whom were 18 to 55 years old. Read more at the NY Post.